Cartesian Therapeutics (RNAC)
NASDAQ:RNAC
Want to see RNAC full AI Analyst Report?
RNAC Stock Chart & Stats
$7.04
-$0.34(-1.95%)
At close: 4:00 PM EST
$7.04
-$0.34(-1.95%)
Day’s Range― - ―
52-Week Range$5.60 - $15.57
Previous CloseN/A
Volume45.37K
Average Volume (3M)261.29K
Market Cap
$182.26M
Enterprise Value$58.10M
Total Cash (Recent Filing)$118.64M
Total Debt (Recent Filing)$11.86M
Price to Earnings (P/E)―
Beta2.26
Next Earnings
Aug 06, 2026EPS Estimate
-0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.46
Shares Outstanding29,302,729
10 Day Avg. Volume211,613
30 Day Avg. Volume261,294
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-1.48
Price to Sales (P/S)66.95
P/FCF Ratio-2.36
Enterprise Value/Market Cap0.32
Enterprise Value/Revenue32.73
Enterprise Value/Gross Profit-5.27
Enterprise Value/Ebitda-0.86
Forecast
1Y Price Target
$34.00Price Target Upside382.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-3.29
Revenue Forecast (FY)$716.17K
Bulls Say, Bears Say
Bulls Say
MRNA-engineered Cell Therapy PlatformCartesian’s core mRNA-based platform that reprograms patient immune cells ex vivo is a durable fundamental advantage. Non‑permanent modification can reduce long‑term safety/regulatory hurdles versus permanent gene edits, enabling repeated dosing and broader applicability across autoimmune indications if clinical proof emerges.
Focused Autoimmune PipelineA concentrated pipeline targeting autoimmune diseases like myasthenia gravis provides strategic focus on high unmet‑need markets. This allows efficient allocation of clinical resources and clearer go/no‑go decision points, increasing the chance that positive trial readouts translate into durable clinical and commercial value over the medium term.
Modest Reported Debt And Sizable AssetsLow absolute debt and meaningful reported assets provide structural optionality: the company can access financing or partner deals from a less leveraged position, and assets (cash, IP, inventory) can support continued R&D or be used as collateral, preserving strategic flexibility over several quarters.
Bears Say
Heavy Operating Cash BurnPersistent, large negative operating and free cash flow indicates the business cannot self‑fund development. This creates ongoing dependence on external financing or partnerships, increasing dilution risk and potentially forcing pace reductions in clinical programs if capital access tightens over the next 2–6 months.
Declining Revenue And Negative MarginsA sharp revenue decline and sustained negative gross and net margins weaken earnings quality and limit any near‑term ability to fund operations internally. For a clinical‑stage biotech, shrinking non‑grant/commercial revenue heightens reliance on capital markets and undermines resilience against execution delays.
Negative Equity And Recapitalization RiskSubstantial negative shareholders' equity reflects accumulated deficits and raises structural recapitalization risk. Over the medium term this heightens probability of dilutive financings, restructurings, or restrictive financing terms, which can constrain strategic options and partner negotiations across multiple quarters.
Cartesian Therapeutics News
RNAC FAQ
What was Cartesian Therapeutics’s price range in the past 12 months?
Cartesian Therapeutics lowest stock price was $5.60 and its highest was $15.57 in the past 12 months.
What is Cartesian Therapeutics’s market cap?
Cartesian Therapeutics’s market cap is $182.26M.
When is Cartesian Therapeutics’s upcoming earnings report date?
Cartesian Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 94 days.
How were Cartesian Therapeutics’s earnings last quarter?
Cartesian Therapeutics released its earnings results on Apr 30, 2026. The company reported -$1.46 earnings per share for the quarter, missing the consensus estimate of -$0.87 by -$0.59.
Is Cartesian Therapeutics overvalued?
According to Wall Street analysts Cartesian Therapeutics’s price is currently Undervalued.
Does Cartesian Therapeutics pay dividends?
Cartesian Therapeutics does not currently pay dividends.
What is Cartesian Therapeutics’s EPS estimate?
Cartesian Therapeutics’s EPS estimate is -0.87.
How many shares outstanding does Cartesian Therapeutics have?
Cartesian Therapeutics has 29,302,729 shares outstanding.
What happened to Cartesian Therapeutics’s price movement after its last earnings report?
Cartesian Therapeutics reported an EPS of -$1.46 in its last earnings report, missing expectations of -$0.87. Following the earnings report the stock price went down -3.864%.
Which hedge fund is a major shareholder of Cartesian Therapeutics?
Currently, no hedge funds are holding shares in RNAC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cartesian Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.00 (382.95% Upside)
$34.00 (382.95% Upside)
Blogger Sentiment
Bullish
RNAC Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 22.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.5%
Last 30 Days ▲ 25.8%
Last 30 Days ▲ 25.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.95%
12-Months-Change
Fundamentals
Return on Equity
279.62%
Trailing 12-Months
Asset Growth
-29.51%
Trailing 12-Months
Company Description
Cartesian Therapeutics
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
RNAC Stock 12 Month Forecast
Average Price Target
$34.00
▲(382.95% Upside)
Technical Analysis
Puma Biotechnology
―
DBV Technologies SA - American
―
Voyager Therapeutics
―
Atea Pharmaceuticals
―
Vor Biopharma
―
Ownership Overview
44.29% Insiders
7.27% Mutual Funds
0.04% Other Institutional Investors
45.48% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---